Neoplasms
Conditions
Keywords
Advanced malignancies, TNBC, DLBCL, Gastric cancer
Brief summary
The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard agents. The purpose of this study Part B is: Determine the safety, tolerability, pharmacokinetics (PK) and maximum tolerated dose (MTDG-CSF) of BAY1143572 with concurrent administration of the granulocyte colony-stimulating factors (G-CSF) in an intermittent and continuous dosing schedule in subjects with advanced malignancies.
Interventions
DRUGBAY1143572
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects aged \>/=21 years * Dose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria). * Expansion phase only: Subjects with advanced, histologically or cytologically confirmed gastric cancer, triple negative breast cancer (TNBC), or diffuse large B-cell lymphoma (DLBCL), who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria). * Archival tumor tissue to conduct molecular and / or genetic studies must be collected from all study subjects enrolled in this study. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Life expectancy of at least 12 weeks * Adequate bone marrow, liver, and renal functions as assessed by laboratory analysis to be conducted within 7 days prior to the first dose of study drug * International normalized ratio (INR) and partial thromboplastin time (PTT) \</=1.5 times ULN (upper limit of normal)
Exclusion criteria
* Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study * History of cardiac disease including congestive heart failure \> New York Heart Association (NYHA) Class II, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months) or myocardial infarction within the past 6 months and cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers and digoxin; evidence for uncontrolled coronary artery disease (e.g. angina pectoris, myocardial infarction within 6 months prior to study entry, major regional wall motion abnormalities upon baseline echocardiography) * Previous pulmonary embolism within 12 months prior to study entry * Uncontrolled hypertension defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg on 2 or more consecutive blood pressure readings, despite optimal medical management * Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C * Known history of human immunodeficiency virus (HIV) infection * Chronic or active hepatitis B or C, requiring antiviral therapy * Active clinically serious infections of \> Grade 2 and/or active infections that require treatment with systemic agent * Uncontrolled seizure disorder requiring therapy (such as steroids or anti-epileptics with significant CYP interaction) * Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of \> Grade 2 within 4 weeks prior to the first dose of study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events as a measure of safety and tolerability | Up to 2 years | — |
| Maximum tolerated dose (MTD) of BAY1143572 | Up to 1 year | In Part A: Maximum tolerated dose (MTD) of BAY1143572 In Part B; Maximum tolerated dose ( MTD) with G-CSF of BAY114357 The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during cycle 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration-time curve from time zero to infinity (AUC) | Cycle 1, Day 1 and Day 15 (each cycle is 28 days) | — |
| Time of maximum observed concentration (tmax) | Cycle 1, Day 1 and Day 15 (each cycle is 28 days) | — |
| Maximum total drug concentration (Cmax) | Cycle 1, Day 1 and Day 15 (each cycle is 28 days) | — |
| Biomarker evaluation by determination of MYC protein expression and PCNA mRNA | Cycle 1, Day 1, Day 8 and Day 15 (each cycle is 28 days) | PCNA: proliferating cell nuclear Antigen mRNA: messenger ribonucleic acid |
| Tumor response based on RECIST 1.1 or Cheson 2007 criteria | Up to 100 weeks | — |
| Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24) | Cycle 1, Day 1 and Day 15 (each cycle is 28 days) | — |
Countries
Singapore, South Korea, Taiwan, United States
Outcome results
None listed